Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.

By G. Ruiz-Palacios, I. Pérez-Schael, F. Velázquez, Héctor J Abate, T. Breuer, S. C. Clemens, B. Cheuvart, F. Espinoza, P. Gillard, B. Innis and 26 more. New England Journal of Medicine, 2006

1,819 citations recorded by the source corpus.

Subfields: Epidemiology, Food Science, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/97b130c6add7bd62b2495472c8cac74f5dbcce71

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

M. Tomblyn
T. Chiller
R. Gress
H. Einsele
K. Sepkowitz
J. Storek
J. Wingard
Jo-Anne H. Young

Citations in the corpus

Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000–2013 (2016, background): “cines (RotaTeq, Merck & Co and Rotarix, GSK Biologicals) have been licensed in >100 countries worldwide [1, 2].”
Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). (2009, background): “The efficacy of the licensed formulation of RV1 has been evaluated in two large phase III trials among healthy infants, one conducted in 11 Latin American countries (109) and one conducted in six European countries (110) (Table 1).”
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplant Recipients: A Global Perspective (2009, background): “RV1 is a human strain that is available as a 2-dose series for use in children at 2 and 4 months of age [736-738].”